BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, September 25, 2023
Home » Blogs » BioWorld Perspectives » Where’s Superman When He’s Needed?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Antibiotic

Where’s Superman When He’s Needed?

April 30, 2013
By Mari Serebrov
No Comments

blog 4-30-13Look! Up in the sky! It’s a bird! It’s a plane! It’s . . . another superbug.

The invasion of the multidrug-resistant superbugs is not a nightmare in the making. It’s already here. And it could be years before a new superhero lands in Metropolis to knock out the worst of the worst of these villains that are set on world domination.

In a twist on the usual comic book tale, the super-resistant strains of CRE, malaria and tuberculosis threatening the world today are not the work of a mad scientist scheming away in a remote underground lab. They are a force of nature – helped along by our over-reliance on cheap, decades-old anti-infectives.

But scientists could hold the answer to stopping the bad guys in their tracks. “All” they need to do is identify a superhero, or discover a form of kryptonite, to strip the nasty bugs of their power. The trouble is that many of the scientists who know these bugs, and the big pharma firms the scientists work for, are ignoring the problem.

That wasn’t always the case. In years gone by, big pharma was on the frontlines of the pathogen battle. Then the generics took over the fight, and the cost and time involved in developing new drugs soared. As a result, big pharma retreated – to a hero-for-hire industry that’s focused on blockbuster drugs that can command high prices, multiple indications and long-term use.

Unfortunately, the heroes that chase down superbugs, especially those terrorizing developing countries, don’t fit that costume. They have to be affordable. And their use has to be limited, so there can be no indiscriminate prescribing, off-label promotion or expanded indications. Otherwise, the bugs will learn the secrets of their powers and devise a way around them.

When big pharma scientists redirected their X-ray vision to blockbuster drugs, they created a brain drain in the R&D necessary to identify a new breed of superheroes to take on drug-resistant bugs. Some of the missing-in-action scientists were the ones who had discovered useful molecules and figured out how the bugs evolve their super resistance. When they fled Metropolis, they took that knowledge with them.

It will take many, many years to overcome the brain drain, Helen Boucher, director of the Infectious Diseases Fellowship Program at Tufts Medical Center, told BioWorld. “If we ever can,” she added.

Meanwhile, as biotech startups scramble to find the money and race against the clock to fill in the knowledge gaps to develop a new brand of hero that might appear on the scene in another decade or so, the world continues to face emerging strains of virile superbugs that make yesterday’s superhero anti-infectives look like impotent has-beens.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing